Elena Dudukina, Elvira V Brâuner, CæcilieB Christiansen, Stine H Mogensen, Mona E Hervig, Stine Ulsø, Martin Z Larsen
{"title":"Associations between mRNA COVID-19 vaccination and urticaria: a nationwide registry-based cohort study in Denmark.","authors":"Elena Dudukina, Elvira V Brâuner, CæcilieB Christiansen, Stine H Mogensen, Mona E Hervig, Stine Ulsø, Martin Z Larsen","doi":"10.1177/14034948251333901","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the association between mRNA COVID-19 vaccination and the risk of urticaria.</p><p><strong>Study design: </strong>Nationwide observational cohort study.</p><p><strong>Setting: </strong>Healthcare registers in Denmark.</p><p><strong>Participants: </strong>The vaccinated cohort included Danish residents aged ⩾5 years who received at least one dose of Comirnaty (Pfizer-BioNTech, BNT) or Spikevax (Moderna, MOD) in December 2020 to July 2023; the pre-pandemic (2017-19) general population aged ⩾5 years formed the comparator cohort.</p><p><strong>Methods: </strong>Urticaria-free participants were followed from the vaccination date until the earliest of the incident chronic or other types of urticaria diagnosis, COVID-19 infection, end of the 90-day outcome risk window, death, emigration, or October 2023. The expected number of urticaria events was computed using indirect standardisation of the pre-pandemic urticaria incidence rates. Standardised incidence ratios (SIRs) with corresponding 95% confidence intervals (CIs) were calculated overall and across sex, age and vaccine sequence-specific strata.</p><p><strong>Results: </strong>We ascertained 4,700,301 vaccinated and 5,480,146 pre-pandemic comparators. Following all vaccine product sequences, SIRs (95% CI) were 0.83 (0.71-0.96) for chronic urticaria and 1.14 (95% CI 1.03-1.25) for other types of urticaria. Among MOD schedule adherers, the risk was three to fourfold increased for chronic (SIR 3.00, 95% CI 2.27-3.88) and other types of urticaria (SIR 3.65, 95% CI 3.06-4.31). Sensitivity analyses of dose specific effects confirmed a fourfold increased risk after MOD vaccine sequence but not BNT.</p><p><strong>Conclusions: </strong>Following the most recent mRNA vaccination dose, MOD vaccine schedule adherers had a higher than expected incidence of chronic and other types of urticaria. We found no association between BNT vaccination schedule and increased risk of urticaria.</p>","PeriodicalId":49568,"journal":{"name":"Scandinavian Journal of Public Health","volume":" ","pages":"14034948251333901"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/14034948251333901","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To investigate the association between mRNA COVID-19 vaccination and the risk of urticaria.
Study design: Nationwide observational cohort study.
Setting: Healthcare registers in Denmark.
Participants: The vaccinated cohort included Danish residents aged ⩾5 years who received at least one dose of Comirnaty (Pfizer-BioNTech, BNT) or Spikevax (Moderna, MOD) in December 2020 to July 2023; the pre-pandemic (2017-19) general population aged ⩾5 years formed the comparator cohort.
Methods: Urticaria-free participants were followed from the vaccination date until the earliest of the incident chronic or other types of urticaria diagnosis, COVID-19 infection, end of the 90-day outcome risk window, death, emigration, or October 2023. The expected number of urticaria events was computed using indirect standardisation of the pre-pandemic urticaria incidence rates. Standardised incidence ratios (SIRs) with corresponding 95% confidence intervals (CIs) were calculated overall and across sex, age and vaccine sequence-specific strata.
Results: We ascertained 4,700,301 vaccinated and 5,480,146 pre-pandemic comparators. Following all vaccine product sequences, SIRs (95% CI) were 0.83 (0.71-0.96) for chronic urticaria and 1.14 (95% CI 1.03-1.25) for other types of urticaria. Among MOD schedule adherers, the risk was three to fourfold increased for chronic (SIR 3.00, 95% CI 2.27-3.88) and other types of urticaria (SIR 3.65, 95% CI 3.06-4.31). Sensitivity analyses of dose specific effects confirmed a fourfold increased risk after MOD vaccine sequence but not BNT.
Conclusions: Following the most recent mRNA vaccination dose, MOD vaccine schedule adherers had a higher than expected incidence of chronic and other types of urticaria. We found no association between BNT vaccination schedule and increased risk of urticaria.
期刊介绍:
The Scandinavian Journal of Public Health is an international peer-reviewed journal which has a vision to: publish public health research of good quality; contribute to the conceptual and methodological development of public health; contribute to global health issues; contribute to news and overviews of public health developments and health policy developments in the Nordic countries; reflect the multidisciplinarity of public health.